Inhibrx Biosciences INBX
NASDAQ INBX
$97.71 +2.41 (+2.53%)
As of: Oct 21, 2026 · 10:25 AM EDT

Inhibrx Biosciences (INBX) Non-Current Debt (2023 - 2026)

Updated

Inhibrx Biosciences' Non-Current Debt was $176.29 million in Q2 2026, up 77.6% from $99.28 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) Non-Current Debt (2023 - 2026) Analysis & Trends

At the end of FY2025, Non-Current Debt at Inhibrx Biosciences came in at $100.56 million.

  • In earlier years, Non-Current Debt was $206.97 million in FY2023.
  • The Q2 2026 figure marks the highest quarterly Non-Current Debt since Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Eli Lilly 1,132.34 Bn 1,100.93 Bn 19.71 Bn 47.86 Bn
2 Johnson & Johnson 615.91 Bn 534.44 Bn 17.26 Bn 37.34 Bn
3 AbbVie 505.47 Bn 478.59 Bn 12.70 Bn 62.48 Bn
4 Merck 368.25 Bn 322.63 Bn 12.21 Bn 51.08 Bn
5 Novartis Ag 298.18 Bn 262.17 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn 23.68 Bn
7 Amgen 236.22 Bn 191.62 Bn 7.24 Bn 51.86 Bn
8 Gilead Sciences 190.68 Bn 164.87 Bn 6.22 Bn 23.83 Bn
9 Pfizer 170.14 Bn 116.79 Bn 10.94 Bn 60.50 Bn
10 Inhibrx Biosciences 1.53 Bn 934.07 Mn - 176.29 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 176.29 Mn
Dec 31, 2025 100.56 Mn
Sep 30, 2025 99.92 Mn
Jun 30, 2025 99.28 Mn
Mar 31, 2025 98.65 Mn
Dec 31, 2023 206.97 Mn
API Access

Inhibrx Biosciences Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=INBX&period=max&api_key=YOUR_API_KEY